Bioequivalence Study of BGM0504 Injection

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Feb 12, 2026 to Apr 9, 2026
    • Start date: Dec 23, 2025 to Dec 29, 2025
    • Eligibility criteria expanded, about 14 words
    • Site details revised
    • Collaborators shortened, about 4 words
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).
Trial Details
NCT Number NCT07382908
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions
(from sponsor)		 Overweight/Obesity
Related terms Obesity, Overweight
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov